A proteogenomic study of 99 never-smoking Korean patients with EGFR- and ALK-wildtype LUAD identified four molecular subgroups with distinct clinical outcomes, based on previously defined tumour and microenvironment signatures applied to transcriptome and proteome data [92]. This evidence concerns the gene ALK and neoplasm.